Last reviewed · How we verify
NCT04015206: IPT-GinMD
Effectiveness of IPT-G in Major Depression
NA trial testing Group Interpersonal Psychotherapy in Depressive Disorder, Major in 18 participants. Terminated before completion.
20 April 2020
Quick facts
| Lead sponsor | Hospital de Clinicas de Porto Alegre |
|---|---|
| Phase | NA |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 18 |
| Start date | 25 August 2019 |
| Primary completion | 20 April 2020 |
| Estimated completion | 20 March 2021 |
| Sites | 1 location across Brazil |
Drugs / interventions tested
- Group Interpersonal Psychotherapy
Conditions studied
- Depressive Disorder, Major — all drugs for Depressive Disorder, Major →
Sponsor
Hospital de Clinicas de Porto Alegre
Who can join
Adults 18 to 65, any sex, with Depressive Disorder, Major. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Although antidepressants are the primary treatment for major depression, response and remission rates are unsatisfactory. The primary objective of this study is to identify if adding interpersonal group therapy (IPT-G) to the usual psychopharmacological and clinical management treatment will improve depressive symptoms in major depression outpatients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04015206
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Group Interpersonal Psychotherapy
Trials testing the same drug.
- NCT04580901 — IPT-G for Mums With Postpartum Depression · NA · completed
Other recruiting trials for Depressive Disorder, Major
Currently open trials in the same condition.
- NCT07227454 — A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder · Phase 3 · recruiting
- NCT07258485 — A Study to Evaluate Sleep Electroencephalogram (EEG) Features (Brain Activity While Sleeping) in Participants With Major · recruiting
- NCT07059234 — The Motor Activity - Subjective Energy (MASE) Project · NA · recruiting
- NCT06982820 — Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia · NA · recruiting
- NCT05553353 — Dosing rTMS for Depression Post-SCI · NA · recruiting
Other Hospital de Clinicas de Porto Alegre trials
Trials by the same sponsor.
- NCT07469722 — POcus INTERvention for Tailoring Diuretic Strategy in Acute Decompensated Heart Failure · Phase 2, PHASE3 · not yet recruiting
- NCT07264179 — Tracheal Cuff Pressure and Postoperative Complications: A Prospective Observational Study. · not yet recruiting
- NCT07052058 — Triple-Blind Randomized Clinical Trial of Tocilizumab vs Placebo: Potential Use of an IL-6 Antagonist as an Adjuvant to · Phase 2 · not yet recruiting
- NCT06953128 — General Versus Regional Anesthesia in Peripheral Arterial Surgery · NA · not yet recruiting
- NCT06934707 — Meal Frequency and Glycemic Control in Individuals With Type 1 Diabetes · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04015206 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospital de Clinicas de Porto Alegre
- Last refreshed: 25 March 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04015206.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing